Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04073147
Title Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma (VENOBI-CNS)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Klinikum Stuttgart

central nervous system lymphoma


Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.